IP Verse

Method And Composition For Treating Ocular Hypertension And Glaucoma - EP3205334

The patent EP3205334 was granted to AGC on Apr 29, 2020. The application was originally filed on May 28, 2009 under application number EP17000440A. The patent is currently recorded with a legal status of "Revoked".

EP3205334

AGC
Application Number
EP17000440A
Filing Date
May 28, 2009
Status
Revoked
Mar 26, 2025
Grant Date
Apr 29, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEJan 26, 2021ELKINGTON AND FIFEADMISSIBLE

Patent Citations (28) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0850926
DESCRIPTIONEP0969846
DESCRIPTIONEP1011728
DESCRIPTIONEP1115406
DESCRIPTIONEP1321144
DESCRIPTIONEP1349580
DESCRIPTIONEP1547599
DESCRIPTIONEP1666043
DESCRIPTIONEP1825855
DESCRIPTIONEP1829545
DESCRIPTIONEP1905453
DESCRIPTIONEP1916002
DESCRIPTIONUS2007248697
DESCRIPTIONUS5409125
DESCRIPTIONUS5614172
DESCRIPTIONUS5807892
DESCRIPTIONUS5886035
DESCRIPTIONUS6096783
DESCRIPTIONUS6241124
DESCRIPTIONUS6344477
DESCRIPTIONWO2007042262
OPPOSITIONEP1321144
OPPOSITIONEP1825855
OPPOSITIONUS2005287325
OPPOSITIONWO0003736
SEARCHEP1321144
SEARCHEP1825855
SEARCHWO0003736

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "DuoTrav", drugs.com, URL: https://www.drugs.com/uk/duotrav.html-
OPPOSITION- Anonymous, "Ganfort Procedural steps and scientific information after the authorisation", European Medicines Agency, (2012), pages 1 - 8, XP055775100-
OPPOSITION- Anonymous, "Guideline on the categorisation of extension applications (EA) versus variations applications (V)", EUROPEAN COMMISSION, (20031000), pages 1 - 10, XP055775088-
OPPOSITION- Anonymous, "Summary of Product Characteristics - GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container.", Allergan Ltd.,, (20170601), pages 1 - 9, XP055775079-
OPPOSITION- Anonymous, "Summary of Product Characteristics Taptiqom 15 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container.", Santen UK Limited, (20180201), pages 1 - 9, XP055775092-
OPPOSITION- E EGOROV A ROPO, "Adjunctive use of tafluprost with timolol provides additive effects for reduction in intraocular pressure in patients with glaucoma", Acta Ophthalmol, (20070000), vol. 85, no. s240-
OPPOSITION- "General requirements for dosage forms Ophthamic preparations", World Health Organization, The International Pharmacopoeia THIRD EDITION, Volume 5, Geneva, World Health Organization, (2003), pages 7 - 11, XP055775213-
OPPOSITION- Higginbotham E J; Diestelhorst M; Pfeiffer N; Rouland J F; Alm A, "The Efficacy and Safety of Unfixed and Fixed Combinations of Latanoprost and Other Antiglaucoma Medications", Surv Ophthalmol, (20020800), vol. 47, no. Suppl.1, pages S133 - S140, XP055461693-
OPPOSITION- Pfizer Limited, "Xalacom eye drops, solution", (20150716), pages 1 - 12, URL: https://www.medicines.org.uk/emc/medicine/7735/SPC/Xalacom+eye+drops,+solution/, XP055461686-
OPPOSITION- Schuman J S; Katz G J; Lewis R A; Henry J C; Mallick S; Wells D T; Sullivan E K; Landry T A; Bergamini M V W; Robertson S M, "Efficacy and Safety of a Fixed Combination of Travoprost 0,004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension", American Journal of Ophthalmology,, (20050000), pages 242.e1 - 242.e11, XP027729492-
OPPOSITION- BRASNU E et al., "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (20080404), vol. 33, pages 303 - 312, XP009108708
OPPOSITION- KUPPENS E V M et al., "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, (19950000), vol. 79, pages 339 - 342, XP009108698
SEARCH- BRASNU E ET AL., "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (200804), vol. 33, no. 4, pages 303 - 312, XP009108708 [Y] 1-14 * the whole document *
SEARCH- KUPPENS E V M ET AL., "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, (1995), vol. 79, pages 339 - 342, XP009108698 [A] 1-14 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents